Primary Insomnia Clinical Trial
— CEBATIOfficial title:
A Randomized, Open Label, Sleep Hygiene Controlled 6-Week Study to Compare the Efficacy of Four (CBT-I, FOA, Combined CBT-I and FOA and Sleep Hygiene) Different Behavioral Approaches for the Treatment of Adult Subjects With Insomnia
Verified date | March 2023 |
Source | Pacific Institute of Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study compares the efficacy of four different types (Cognitive Behavior Therapy for Insomnia (CBT-I); Focus of Attention (FOA); Combined CBT-I and FOA; and Sleep Hygiene (control group) for the treatment of insomnia. This study is a randomized, open label study, and the participants are asked to assess the benefits they get from the intervention. This study involve 6 weekly in person one-to-one sessions after screening and completion of the 1-week, 3-month, 6-month and 12-month follow-up assessment. The trained study staff will administering the treatment. The Research Department will administer the outcome measures. The review of insomnia improvement will be assessed at at end of treatment, 3 months, 6 months and 12 months follow-up.
Status | Terminated |
Enrollment | 160 |
Est. completion date | July 1, 2022 |
Est. primary completion date | November 1, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 72 Years |
Eligibility | Inclusion Criteria: - Male and female outpatients who are 18 or older to 72 years. Insomnia Severity Index > or = 10 - Meet diagnostic criteria for Insomnia Disorder per DSM-5 Willing and able to sign Informed consent form Not planning on moving away from the area for the subsequent 12 weeks. Exclusion Criteria: - Participants who answer "yes" to any of the following will be excluded: - Females who are lactating or who are pregnant - Night shift workers, and individuals who nap 3 or more times per week over the preceding month - Consumption of caffeine beverages (i.e. tea, coffee, or cola) comprising usually more than 5 cups or glasses per day - Participation in another trial for insomnia - Persons unable to complete the study questionnaires and psychological tests - Persons who are unable to participate for the entire duration of the study, or in the opinion of the investigators, are likely to be non-compliant with the obligations inherent in the trial participation - Persons self-describing with severe anxiety or severe depression (BDI score of 29 or higher) or severe anxiety (BAI score of 36 or higher). - Persons with a history of epilepsy, seizures, or dementia - Any significant, severe or unstable, acute or chronically progressive medical or surgical condition - Serious head injury or stroke within the past year - Current alcohol or substance abuse/dependence (must have >90 days of sobriety) - Presence of other neurological disorders (e.g., multiple sclerosis, Parkinson's Disease) - Presence of an untreated or unstable medical or psychiatric comorbid condition (e.g., major depressive disorder or psychotic disorder requiring admission within the last two years). People using psychotropic medication, hypnotic or sedative medications may be included if they are on a stable dosage for the last 2 months prior to the study, if the dose remains stable throughout the study, and if the medication is judged to not interfere with the study outcomes. - Currently on medications known to produce insomnia (e.g., stimulants) - Sleep apnea (AHI >15) or previous diagnosis of sleep apnea. Study participants who use a continuous positive airway pressure (CPAP) device for sleep apnea will be eligible for participation if they are below the apnea/hypopnea cutoff while using CPAP and agree to use the device during study participation. |
Country | Name | City | State |
---|---|---|---|
United States | Puget Sound Psychiatric Center | Bothell | Washington |
United States | Puget Sound Psychiatry Center | Bothell | Washington |
Lead Sponsor | Collaborator |
---|---|
Pacific Institute of Medical Sciences |
United States,
Becher AK, Hohne M, Axmacher N, Chaieb L, Elger CE, Fell J. Intracranial electroencephalography power and phase synchronization changes during monaural and binaural beat stimulation. Eur J Neurosci. 2015 Jan;41(2):254-63. doi: 10.1111/ejn.12760. Epub 2014 — View Citation
Cahn BR, Polich J. Meditation states and traits: EEG, ERP, and neuroimaging studies. Psychol Bull. 2006 Mar;132(2):180-211. doi: 10.1037/0033-2909.132.2.180. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Self Report Sleep Measures | SRSM: assess overall quantity of sleep satisfaction on the Self Report Sleep Measures. | through study completion, an average of 1 year | |
Secondary | Insomnia Severity Index | ISI: assess the severity of insomnia. | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02243501 -
Better Nights, Better Days for Typically Developing Children
|
N/A | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Completed |
NCT00770510 -
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
|
Phase 2/Phase 3 | |
Completed |
NCT00520832 -
A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys
|
Phase 2 | |
Recruiting |
NCT00415714 -
Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia
|
N/A | |
Terminated |
NCT00420810 -
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
|
Phase 3 | |
Completed |
NCT00178048 -
Paroxetine in the Treatment of Chronic Primary Insomnia
|
Phase 4 | |
Completed |
NCT00816673 -
Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs
|
Phase 2 | |
Completed |
NCT01957111 -
Metabolomics of Insomnia-Related Hyperarousal
|
N/A | |
Completed |
NCT01960452 -
A High Density EEG Comparison of Sleep Patterns in Insomnia
|
N/A | |
Completed |
NCT01181232 -
A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients
|
Phase 4 | |
Completed |
NCT00784875 -
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
|
Phase 2 | |
Completed |
NCT00551148 -
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia
|
Phase 2 | |
Completed |
NCT00397189 -
Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
|
Phase 3 | |
Completed |
NCT00352144 -
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
|
Phase 3 | |
Completed |
NCT02290405 -
Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
|
||
Completed |
NCT03314441 -
Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia
|
N/A | |
Completed |
NCT00792298 -
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
|
Phase 2 | |
Completed |
NCT01021852 -
Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
|
Phase 2 | |
Completed |
NCT01719315 -
Neurophysiologic Correlates of Hypersomnia
|